title: Is it worthwhile to add dipivefrin HCl 0.1% to topical beta 1-, beta 2-blocker therapy?
abstract: In a prospective study, the addition of dipivefrin hydrochloride 0.1% twice daily to one eye of 32 patients with early primary open-angle glaucoma or ocular hypertension, maintained on a bilateral beta 1-, beta 2-blocker twice daily, resulted in a significant decrease of mean intraocular pressure (IOP) from 22.7 +/- 3.9 to 20.2 +/- 3.4 mmHg at 1 week (P = 0.0001) and to 21.0 +/- 3.8 mmHg at 12 weeks (P less than 0.02) in the dipivefrin-treated eyes. On the other hand, no significant change was noted in the fellow eyes (from 21.7 +/- 4.1 to 21.6 +/- 4.0 mmHg at 1 week and to 21.3 +/- 4.2 mmHg at 12 weeks). The addition of dipivefrin resulted in an IOP reduction of 2 mmHg or more in 50% and 3 mmHg or more in 19% of the eyes throughout the 12-week therapy. The result of the current study provides a realistic guideline as to what to expect from the common practice of adding dipivefrin hydrochloride to a beta 1-, beta 2-blocker regimen.
authors.affiliation: Kresge Eye Institute, Wayne State University School of Medicine, Detroit, MI 48201.
authors.forename: K A
authors.initials: KA
authors.lastname: Parrow
authors.forename: Y J
authors.initials: YJ
authors.lastname: Hong
authors.forename: D H
authors.initials: DH
authors.lastname: Shin
authors.forename: D X
authors.initials: DX
authors.lastname: Shi
authors.forename: B
authors.initials: B
authors.lastname: McCarty
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D002040:Levobunolol / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D011446:Prospective Studies; D011897:Random Allocation; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use; D014065:Tonometry, Ocular
chemical_list: D000319:Adrenergic beta-Antagonists; D013999:Timolol; C015173:dipivefrin; D002040:Levobunolol; D004837:Epinephrine